Partners4Access BV Celebrates Outstanding Achievements with Multiple Prestigious Awards in 2024
London, 8th August 2024 – Partners4Access, a global leader in pharmaceutical innovation and orphan drug access, is proud to announce that it has been honoured with several prestigious awards in 2024, recognizing our commitment to excellence, innovation, and leadership in the life sciences sector.
A Year of Distinction
In 2024, Partners4Access has garnered accolades from renowned industry bodies, highlighting our unwavering dedication to advancing pharmaceutical research and improving access to life-saving treatments for rare diseases.
Award Highlights:
- Best Global Orphan Drug Access Specialists 2024
Awarded by: GHP Biotechnology Awards
Recognition: This award acknowledges our exceptional efforts in improving global access to orphan drugs, underscoring our role as a leader in this critical sector.
Link: GHP Biotechnology Awards 2024 - Best Pharmaceutical Business of the Year 2024
Awarded by: Corporate America Today & M&A Today Global Awards
Recognition: Honoured by both Corporate America Today and M&A Today, this dual recognition reflects our outstanding business practices, strategic growth, and industry leadership.
Link: Corporate America Today
Link: M&A Today Global Awards - Best Orphan Drug Access Consultancy 2024 – UK
Awarded by: GHP International Life Science Awards
Recognition: This award celebrates our consultancy’s impact on shaping the orphan drug access landscape in the UK, driving positive change for patients with rare diseases.
Link: GHP International Life Sciences Awards 2024 - Most Influential Rare Disease Research MD 2024 (Sophie Schmitz)
Awarded by: Acquisition International AI Influential Businesswoman Awards
Recognition: This individual honour highlights the influence and impact of our leading managing director in the field of rare disease research.
Link: AI Influential Businesswoman Awards 2024 - Pharmaceutical Research Company of the Year – UK
Awarded by: Corporate LiveWire Innovation & Excellence Awards
Recognition: Acknowledging our cutting-edge research, this award underscores our commitment to pioneering new treatments and driving pharmaceutical innovation.
Link: Corporate LiveWire Innovation & Excellence Awards 2024 - Highly Commended ‘Analyst Team of the Year’
Awarded by: BHBIA BOBI Awards
Recognition: This commendation celebrates the analytical expertise and insights provided by our team, which have significantly contributed to our success in the industry.
Link: BOBI Awards 2024 - Best Global Orphan Drug Access Company 2024
Awarded by: SME News Greater London Enterprise Awards
Recognition: This award recognizes our excellence as a global leader in orphan drug access, highlighting our efforts to bridge the gap between innovation and accessibility.
Link: SME News Greater London Enterprise Awards 2024
Commitment to Excellence
These awards reflect Partners4Access’s commitment to transforming the pharmaceutical industry through innovation, strategic vision, and an unwavering dedication to improving patient outcomes worldwide. We are honoured to be recognized across multiple domains and remain steadfast in our mission to lead the way in rare disease and orphan drug, cell and gene therapy access.
Sophie Schmitz, managing partner of Partners4Access commented: “We are thrilled to receive these prestigious awards, which validate the hard work and passion of our entire team. Our mission has always been to make a meaningful impact on patients’ lives, and these accolades inspire us to continue pushing the boundaries of what’s possible in the life sciences.”
About Partners4Access
Partners4Access is a leading global market access consultancy specializing in rare disease, cell therapy, gene therapy and orphan drug access. With a global presence, we are dedicated to supporting our clients and access to life-changing therapies to patients worldwide.
For more information, please visit our website at www.partners4access.com
Contact:
Georgie Rack
Head of Operations
[email protected]
+44 7854941615
